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Edited by Sandro SonninoAbstract Eﬃcacious cationic transfection lipids usually need
either DOPE or cholesterol as co-lipid to deliver DNA inside
the cell cytoplasm in non-viral gene delivery. If both of these
co-lipids fail in imparting gene transfer properties, the cationic
lipids are usually considered to be transfection ineﬃcient. Here-
in, using both the reporter gene assay in CHO, COS-1 and
HepG2 cells and the whole cell histochemical X-gal staining as-
say in representative CHO cells, we demonstrate that common
co-lipids DOPE, Cholesterol and DOPC, when act in synergy,
are capable of imparting improved gene transfer properties to
a novel series of cationic lipids (1–5). Contrastingly, lipids 1–5
became essentially transfection-incompetent when used in combi-
nation with each of the pure co-lipid components alone.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Clinical success of gene therapy critically depends upon the
bio-safety and eﬃcacies of transfection vectors used in deliv-
ering therapeutic genes into the body cells [1–3]. Broadly
speaking, the contemporary transfection vectors are classiﬁed
into two major categories: viral and non-viral. Although, re-
combinant retroviral vectors in particular, are remarkably
eﬃcient in transfecting body cells [4,5] they are potentially
capable of: generating replication competent virus through
various recombination events with the host genome; inducing
inﬂammatory and adverse immunogenic responses; producing
insertional mutagenesis through random integration into the
host genome; etc. [6–9]. Recently, it has been reported that
retrovirus vector insertion near the promoter of the proto-
oncogene LMO2 in two human patients with X-linked severeAbbreviations: DMEM, Dulbeccos modiﬁed Eagles medium; ONPG,
o-nitrophenyl-b-D-galactopyranoside; FBS, fetal bovine serum;
DOPE, 1,2-dioleyl-sn-glycero-3-phosphoethanolamine; DOPC, 1,2-
dioleyl-sn-glycero-3-phosphocholine; X-gal, 5-bromo-4-chloro-
3-indolyl-b-D-galactopyranoside; MTT, 3-(4,5,-dimethylthiazol-2-yl)-
2,5-diphenyltetrazoliumbromide; PBS, phosphate-buﬀered saline
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doi:10.1016/j.febslet.2004.11.116combined immunodeﬁciency (SCID-XI) is capable of trigger-
ing deregulated premalignant cell proliferation with unex-
pected frequency [10]. Conversely, cationic lipids, because
of their least immunogenic nature, robust manufacture, abil-
ity to deliver large pieces of DNA and ease in handling &
preparation techniques, are ﬁnding increasing uses as the
gene transfer reagents of choice in non-viral gene therapy
[11–35].
A number of previously reported investigations [11,16–28],
including our own [12–15,29–35], have demonstrated that
cationic transfection lipids, in general, need to be used in
combination with either 1,2-dioleoyl-sn-glycero-3-phospho-
ethanolamine (DOPE) or Cholesterol as an auxiliary lipid
(co-lipid). During screening of libraries of cationic lipids
for their transfection properties, if none of these two co-lipids
impart gene transfection properties, the lipids are usually
considered to be transfection ineﬃcient. Herein, using a no-
vel series of non-glycerol backbone based cationic lipids
with polar 2-hydroxyethyl and 2-aminoethyl head-group
functionalities (1–5, Fig. 1), we demonstrate that the com-
mon co-lipids DOPE, cholesterol and 1,2-dioleyl-sn-gly-
cero-3-phosphocholine (DOPC), when act in synergy, are
capable of imparting high gene transfer properties to cat-
ionic lipids 1–5. Contrastingly, both the reporter gene
expression assay in COS-1, CHO and HepG2 cells and
the whole cell histochemical X-gal staining assay in repre-
sentative CHO cells convincingly demonstrated that the high
gene transfection properties of these new lipids were essen-
tially abolished when used in combination with equimolar
amounts of individual pure co-lipid components alone. Elec-
trophoresis gel patterns in DNase I sensitivity assay are
consistent with the notion that the high transfection proper-
ties of the present cationic lipids in association with the
equimolar amounts of DOPE, cholesterol and DOPC may
partly originate due to reduced DNase I susceptibility of
the corresponding lipoplexes. Taken together, the present
ﬁndings support the notion that use of common co-lipids
in synergy may turn out to be rewarding in future design
of novel liposomal transfection kits for use in non-viral gene
therapy.2. Materials and methods
2.1. General procedures and materials
FABMS data were acquired by the liquid secondary ion mass spec-
trometry (LSIMS) technique using meta-nitrobenzyl alcohol as the
matrix. LSIMS analysis was performed in the scan range 100–1000
amu at the rate of 3 scans/s. 1H NMR spectra were recorded onblished by Elsevier B.V. All rights reserved.
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Fig. 1. Synthesis of cationic lipids 1–5.
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1-Bromotetradecane, 1-bromohexadecane, 1-bromooctadecane, n-
tetradecylamine, n-hexadecylamine, n-octadecylamine were procured
from Lancaster (Morecambe, UK). Unless otherwise stated all re-
agents were purchased from local commercial suppliers and were
used without further puriﬁcation. The progress of the reactions was
monitored by thin-layer chromatography on 0.25 mm silica gel plates.
Column chromatography was performed with silica gel (Acme Syn-
thetic Chemicals, India, 60–120 mesh). Lipofectamine was purchased
from Invitrogen life technologies (USA). Cell culture media, fetal
bovine serum (FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT), polyethylene glycol 8000, o-nitrophenyl-b-D-
galactopyranoside (ONPG) and cholesterol were purchased from
Sigma, St. Louis, USA. NP-40, antibiotics and agarose were
purchased from Hi-media, India. DOPE and DOPC were purchased
from Fluka (Switzerland). Unless otherwise stated all the other re-
agents purchased from local commercial suppliers were of analytical
grades and were used without further puriﬁcation. Purity of all
the ﬁnal lipids (1–5, Fig. 1) was determined to be more than
95% by analytical HPLC (Shimadzu Model LC10A) using a PARTI-
SIL 5 ODS-3 WCS analytical column (4.6 · 250 mm, Whatman
Inc., Clifton, NJ, USA) in two diﬀerent mobile phases. One solvent
system (A) was methanol:acetonitrile:water:triﬂuoroacetic acid in
the ratio 65:10:25:0.05 (v/v) for 15 min with a ﬂow rate of
0.8 mL/min. The other mobile phase (B) was methanol:water: triﬂuo-
roacetic acid in the ratio 75:25:0.05 for 15 min with a ﬂow rate of
0.8 mL/min. Peaks were detected by UV absorption at 219 nm.
Typical retention times in mobile phase B were: 3.62 min (lipid 1);
3.61 min (lipid 2); 3.60 min (lipid 3); 3.69 min (lipid 4); 3.59 min
(lipid 5).
2.2. Synthesis of N-2-aminoethyl-N,N-di-n-hexadecylamine,
N-2-hydroxyethylammonium chloride
2.2.1. Step (a). Synthesis of N,N-di-n-hexadecyl-N-[2-(N-tert-butyl-
oxycarbonyl)aminoethyl]amine (II, Fig. 1). A mixture of 2.2 g
(4.7 mmol) of N,N-di-n-hexadecylamine (I, Fig. 1, prepared conven-
tionally by reﬂuxing one equivalent each of n-hexadecylamine and
n-hexadecyl bromide in ethyl acetate in presence of 1.1 equivalent
of anhydrous potassium carbonate followed by usual work up and
column chromatographic puriﬁcation) and 1.1 g (5.2 mmol) of N-
tert-butoxycarbonyl-2-bromoethylamine (prepared by reacting one
equivalent each of 2-bromoethylamine hydrobromide and BOC-
anhydride in presence of 2.2 equivalent of triethyl amine in 1:1 dichol-
oromethane/N,N-dimethylformamide, v/v, followed by usual work up)
was reﬂuxed in 10 mL ethyl acetate in presence of anhydrous potas-
sium carbonate (1.4 g, 10 mmol) for 48 h. The reaction mixture was
taken in 100 mL chloroform, washed with water (2 · 100 mL), dried
over anhydrous magnesium sulfate and ﬁltered. Chloroform was re-
moved from the ﬁltrate on a rotary evaporator. Silica gel column chro-
matographic puriﬁcation of the resulting residue using 60–120 mesh
silica gel size and 6% acetone in pet ether (v/v) as the eluent aﬀorded
the title compound as light yellow solid (2.0 g, 71% yield, Rf = 0.5,
30:70, v/v, ethyl acetate:pet-ether).1H NMR (200 MHz, CDCI3): d/ppm = 0.9 [t, 6H, CH3–(CH2)12–];
1.2–1.4 [m, 56H, –(CH2)14–]; 1.5 [s, 9H, –C(CH3)3]; 2.4 [t, 4H,
N(CH2–CH2–)2]; 2.5 [t, 2H, N(CH2–CH2–NHBOC –)]; 3.1 [m, 2H,
N(CH2–CH2–NHBOC)]; 4.9 [bm, 1H, NHBOC].
2.2.2. Step (b). Synthesis of N-2-(N-tert-butyloxycarbonyl)amino-
ethyl-N,N-di-n-hexadecylamine-N-2-hydroxyethylammonium chloride
(III, Fig. 1). 0.18 g (329 mmol) of the intermediate tertiary amine
II obtained above in a step was dissolved in huge excess (3 mL)
of 2-chloroethanol and anhydrous K2CO3 (0.22 g, 33 mmol) was
added to the solution. The solution was allowed to reﬂux at 80 C
for 32 h. The reaction mixture was ﬁltered and the unreacted excess
2-choroethanol was removed by repeated chasing with methanol on
a rotary evaporator. The residue upon column chromatographic
puriﬁcation using 60–120 mesh size silica gel and 3–4% methanol
in dichloromethane (v/v) as eluent aﬀorded the title compound as
a white solid (0.08 g, 43% yield, Rf = 0.5, 10% methanol in dichloro-
methane, v/v).
1H NMR(200 MHz, CDCl3): d/ppm = 0.9 [t, 6H, CH3–(CH2)14–];
1.2–1.3 [m, 52H, –CH3 (CH2)13–]; 1.4–1.5 [s, 9H, –CO–O–C(CH3)3];
1.65 [m, 4H, –N+(–CH2–CH2–)2]; 3.4 [m, 4H, –N
+(–CH2–CH2–)2];
3.6 [bm, 6H, –N+–CH2–CH2–NH–Boc; –N
+–CH2–CH2–NH–BOC;
–N+–CH2–CH2–OH ]; 4.0 [m, 2H, –N
+–CH2–CH2–OH]; 5.6 [m, 1H,
–NHBOC]; 6.5 [m, 1H, –N+–CH2–CH2–OH ].
2.2.3. Step (c). Synthesis of N-2-aminoethyl-N,N-di-n-hexadecyl-
amine-N-2-hydroxyethyl ammonium chloride.HCl (lipid 2). The inter-
mediate obtained above in step (b) (0.08 g, 0.14 mmol) was dissolved
in 1.5 mL of methanol and 0.5 mL of 1 N HCl was added at 0 C.
The resulting solution was left stirred at room temperature for 3 h.
Excess HCl was removed by ﬂushing with nitrogen to give the title
compound as a hydrochloride salt. Column chromatographic puriﬁ-
cation using 60–120 mesh size silica gel and 8–10% (v/v) methanol-
chloroform as eluent followed by chloride ion exchange chromatogra-
phy using amberlyst A-26 chloride ion exchange resin aﬀorded lipid 2
as a white solid (0.06 g, 88% yield, Rf = 0.2, 10% methanol in chloro-
form, v/v).
1H NMR(200 MHz, CD3OD): d/ppm = 0.9 [t, 6H, CH3–(CH2)13–];
1.2–1.3 [m, 52H, –CH3(CH2)13–]; 1.65 [m, 4H, –N
+(–CH2–CH2–)2];
3.4 [m, 6H, –N+(–CH2–CH2–)2, –N
+–CH2–CH2–OH]; 3.5–3.65 [bm,
4H, –Nþ–CH 2–CH2–NH
þ
3 ; –N
þ–CH2–CH 2–NH
þ
3 ]; 4.0 [m, 2H, –N
+–
CH2–CH2–OH].
LSIMS (lipid 2): m/z: 554 [M]+ (calcd for C36H78N2O, 83%).2.3. Synthesis of lipids 1 and 3–5
Lipids 1 and 3–5 were prepared following the same detail synthetic
procedure as described above for the representative lipid 2 except using
the appropriate starting secondary amines (I, Fig. 1). All the isolated
intermediates gave spectroscopic data in agreement with their struc-
tures shown in Fig. 1. The 1H NMR and the LSIMS mass spectral data
of lipids 1 and 3–5 are provided below.
2.3.1. N-2-aminoethyl-N,N-di-n-tetradecylamine-N-2- hydroxyethy-
lammonium chloride ÆHCl (lipid 1). 1H NMR(200 MHz, CD3OD):
d/ppm = 0.9 [t, 6H, CH3–(CH2)11–]; 1.2–1.3 [m, 44H, –CH3(CH2)11–];
1.65 [m, 4H, –N+(–CH2–CH2–)2]; 3.4 [m, 6H, –N
+(–CH2–CH2–)2,
–N+–CH2–CH2–OH]; 3.5–3.65 [bm, 4H, –N
þ–CH 2–CH2–NH
þ
3 ; –N
þ–
CH2–CH 2–NH
þ
3 ]; 4.0 [m, 2H, –N
+–CH2–CH2–OH].
LSIMS (lipid 1): m/z: 499 [M + 1]+ (calcd for C32H70N2O, 100%).
2.3.2. N-2-aminoethyl-N,N-di-n-octadecylamine-N-2-hydroxyethy-
lammonium chloride ÆHCl (lipid 3). 1H NMR(200 MHz, CD3OD):
d/ppm = 0.9 [t, 6H, CH3–(CH2)15–]; 1.2–1.3 [m, 60H, –CH3(CH2)15–];
1.65 [m, 4H, –N+(–CH2–CH2–)2]; 3.4 [m, 6H, –N
+(–CH2–CH2–)2,
–N+–CH2–CH2–OH]; 3.5–3.65 [bm, 4H, –N
þ–CH 2–CH2–NH
þ
3 ; –N
þ
–CH2–CH 2–NH
þ
3 ]; 4.0 [m, 2H, –N
+–CH2–CH2–OH].
LSIMS (lipid 3): m/z: 611 [M + 1]+ (calcd for C40H82N2O, 100%).
2.3.3. N-2-aminoethyl-N-oleyl-N-n-octadecylamine-N-2-hydroxyethy-
lammonium chloride ÆHCl (lipid 4). 1H NMR (200 MHz, CD3OD): d/
ppm = 0.9 [t, 6H, CH3–(CH2)15–]; 1.2–1.3 [m, 52H,
–CH3(CH2)15–, CH3–(CH2)6–CH2–CH‚CH–CH2– (CH2)5–]; 1.65
[m, 4H, –N+(–CH2–CH2–)2]; 1.90– 2.1 [m, 4H, –CH2–CH‚CH–
CH2]; 3.4 [m, 6H, –N
+(–CH2–CH2–)2, –N
+–CH2–CH2–OH]; 3.5–3.65
[bm, 4H, –Nþ–CH 2–CH2–NH
þ
3 ; –N
þ–CH2–CH 2–NH
þ
3 ]; 4.0 [m, 2H,
–N+–CH2–CH2–OH]; 5.3 [m, 2H, –CH2–CH‚CH–CH2].
LSIMS (lipid 4): m/z: 609 [M + 1]+ (calcd for C40H80N2O, 100%).
2.3.4. N-2-aminoethyl-N,N-di-n-oleyl-N-2-hydroxyethylammonium
chloride ÆHCl (lipid 5). 1H NMR (200 MHz, CD3OD): d/ppm = 0.9
[t, 6H, CH3–(CH2)15–]; 1.2–1.3 [m, 44H, CH3–(CH2)6–CH2–
K. Mukherjee et al. / FEBS Letters 579 (2005) 1291–1300 1293CH‚CH–CH2–(CH2)5–]; 1.65 [m, 4H, –N
+(–CH2–CH2–)2]; 1.90–2.1
[m, 8H, –CH2–CH‚CH–CH2]; 3.4 [m, 6H, –N
+(–CH2–CH2–)2,
–N+–CH2–CH2–OH]; 3.5–3.65 [bm, 4H, –N
þ–CH 2–CH2–NH
þ
3 ;
–Nþ–CH2–CH 2–NH
þ
3 ]; 4.0 [m, 2H, –N
+–CH2–CH2–OH]; 5.3 [m,
4H, –CH2–CH‚CH–CH2].
LSIMS (lipid 5): m/z: 606 [M]+ (calcd for C40H78N2O, 100%).2.4. Cell culture
COS-1 (SV 40 transformed african green monkey kidney cells),
CHO (Chinese hamster ovary) and HepG2 (human hepatocarcinoma)
cell lines were procured from the National Centre for Cell Sciences
(NCCS), Pune, India. Cells were cultured at 37 C in Dulbeccos mod-
iﬁed Eagles medium (DMEM) with 10% FBS, 50 lg/ml penicillin,
50 lg/ml streptomycin and 20 lg/ml kanamycin in a humidiﬁed atmo-
sphere containing 5% CO2.2.5. Plasmids
pCMV-SPORT-b-gal plasmids were generous gifts from Dr. Leaf
Huang (Department of Pharmacogenetics, University of Pittsburgh,
School of Medicine, Pittsburgh, PA, USA) and Dr. Nalam Madhu-
sudhana Rao (Centre for Cellular and Molecular Biology, Hyderabad,
India). The plasmids were ampliﬁed in DH5a strain of Escherichia coli,
isolated by alkaline lysis procedure and ﬁnally puriﬁed by PEG-8000
precipitation as described previously [14]. The purity of plasmid
was checked by A260/A280 ratio (around 1.9) and 1% agarose gel
electrophoresis.2.6. Preparation of liposomes and lipid–DNA complexes
Cationic lipids and the co-lipids in chloroform were dried under a
stream of N2 gas and vacuum-dessicated for a minimum of 6 h to re-
move residual organic solvent. The dried lipid ﬁlm was hydrated in
sterile deionized water at cationic lipid concentration of 1 mM for a
minimum of 12 h. Liposomes were vortexed to remove any adhering
lipid ﬁlm and probe sonicated until a clear translucent solution formed.
The pDNA solution was added to the liposomes, mixed properly by
pipetting up and down a few times and kept at room temperature
for 15–30 min before use.2.7. In vitro transfection studies
Cells were seeded at a density of 15,000 (for COS-1) and 20000
(for CHO and HepG2) per well in a 96-well plate 18–24 h before
transfection. 0.30 lg of pDNA was complexed with varying amounts
of lipids (to give +/ ratios of 0.1:1, 0.3:1, 1:1, 3:1 and 9:1) in plain
DMEM (total volume made up to 100 ll) for 20–30 min. The com-
plexes were then added to the cells. After 3 h of incubation, 100 ll
of DMEM with 20% FBS was added to the cells. The medium was
changed to complete medium containing 10% FBS after 24 h and
the reporter gene activity was estimated after 48 h. Cells were washed
with phosphate-buﬀered saline (PBS, 100 ll) and lysed in 50 ll lysis
buﬀer (0.25 M Tris–HCl, pH 8.0, 0.5% NP40). The b-galactosidase
activity per well was estimated by adding 50 ll of 2·-substrate solu-
tion (1.33 mg/ml of ONPG, 0.2 M sodium phosphate, pH 7.3, and
2 mM magnesium chloride) to the lysate in a 96-well plate. Absor-
bance of the product ortho-nitrophenol at 405 nm was converted to
b-galactosidase units by using calibration curve constructed using
pure commercial b-galactosidase enzyme. The transfection values re-
ported are the average values from two replicate experiments per-
formed in the same plate on the same day. Each transfection
experiment was performed three times on three diﬀerent days. The
day-to-day variation in transfection eﬃciency was mostly within 2–
3 fold and was dependent on the cell density and condition of the
cells.2.8. Toxicity assay
Cytotoxicities of the lipoplexes prepared from the lipids 1–5 were as-
sessed by the MTT reduction assay as described earlier [14]. The cyto-
toxicity assay was performed in 96-well plates by maintaining the same
ratio of number of cells to amount of cationic lipid, as used in the
transfection experiments. MTT was added 3 h after addition of
cationic lipid to the cells. Results were expressed as percent viabil-
ity = [A540(treated cells)  background/A540(untreated cells)  back-
ground] · 100.2.9. Size measurments
The sizes of liposomes and lipoplexes were measured by photon cor-
relation spectroscopy and electrophoretic mobility on a Zeta sizer 3000
HSA (Malvern UK). The sizes were measured in deionised water with a
sample refractive index of 1.59 and a viscosity of 0.89. The system was
calibrated by using the 200 nm + 5 nm polystyrene polymer (Duke Sci-
entiﬁc Corp., Palo Alto, CA). The diameters of liposomes and lipo-
plexes were calculated by using the automatic mode.
2.10. DNA binding assay
The DNA binding abilities of the present cationic lipids in combina-
tion with varying co-lipids were assessed by the conventional gel retar-
dation assay on a 1% agarose gel (pre-stained with ethidium bromide)
across the varying lipid:DNA charge ratios of 1:1 to 9:1. pCMV-b-gal
(0.30 lg) was complexed with the varying amount of cationic lipids in a
total volume of 20 ll in HEPES buﬀer, pH 7.40, and incubated at
room temperature for 20–25 min. 4 ll of 6· loading buﬀer (0.25% bro-
mophenol blue in 40%, w/v, sucrose in H2O) was added to it and the
resulting solution, (24 ll) was loaded on each well. The samples were
electrophoresed at 80 V for 45 min and the DNA bands were visualized
in the Gel documentation unit.
2.11. DNase I sensitivity assay
Brieﬂy, in a typical assay, pCMV-SPORT-b-gal (1000 ng) was com-
plexed with the varying amounts of the representative cationic lipid 1
and co-lipids (pure and mixed) using the indicated lipid:DNA charge
ratios in Fig. 5 in a total volume of 30 lL in HEPES buﬀer, pH
7.40, and incubated at room temperature for 30 min on a rotary sha-
ker. Subsequently, the complexes were treated with 10 lL DNase I
(at a ﬁnal concentration of 1 lg/mL) in presence of 20 mM MgCl2
and incubated for 20 min at 37 C. The reactions were then halted
by adding EDTA (to a ﬁnal concentration of 50 mM) and incubated
at 60 C for 10 min in a water bath. The aqueous layer was washed
with 50 lL of phenol:chloroform:isoamylalcohol (25:24:1 mixture, v/
v) and centrifuged at 10000 · g for 5 min. The aqueous supernatants
were seperated, loaded (15 lL) on a 1% agarose gel (pre-stained with
ethydium bromide) and electrophoresed at 100 V for 1 h.
2.12. The whole cell histochemical 5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside (X-gal) staining assay
Cells expressing b-galactosidase were histochemically stained with
the substrate X-gal as described previously [14]. Brieﬂy, 48 h after
transfection with lipoplexes in 96-well plates, the cells were washed
two times (2 · 100 lL) with PBS (137 mM NaCl, 2.7 mM KCl,
10 mMNa2HPO4, 2 mMKH2PO4, pH 7.4) and ﬁxed with 0.5% glutar-
aldehyde in PBS (225 lL). After 15 min incubation at room tempera-
ture, the cells were washed again with PBS three times (3 · 250 lL)
and subsequently, were stained with 1.0 mg/mL X-gal in PBS contain-
ing 5.0 mM K3[Fe(CN)6], and 5.0 mM K4[Fe(CN)6] and 1 mMMgSO4
for 2–4 h at 37 C. Blue colored cells were identiﬁed by light micro-
scope (Leica, Germany).3. Results and discussion
3.1. Chemistry
The synthetic process adopted for preparing lipids 1–5 is
shown schematically in Fig. 1. The starting N,N-dialkylamines
(I, Fig. 1) containing appropriate alkyl chain lengths upon
reﬂuxing with tert-butyloxycarbonyl protected 2-bromoethyl-
amine in anhydrous ethyl acetate in presence of potassium car-
bonate followed by usual work-up aﬀorded the intermediate
tertiary amines (II, Fig. 1). The target lipids were prepared
by quaternizing intermediates II with excess of 2-chloroethanol
in presence of potassium carbonate followed by acid deprotec-
tion of quaternized intermediate (III, Fig. 1) and chloride ion
exchange chromatography over Amberlyst A-26. The details
of synthetic processes, spectral and analytical characterizations
of all the intermediates and ﬁnal lipids are provided above un-
der Section 2.
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co-lipids. The ﬁndings in a number of previously reported
investigations [11,16–28] including our own [12–15,29–35],
demonstrated that cationic lipids, in general, need either
DOPE or cholesterol to be used as an auxiliary lipid for trans-
fecting cells. Based on these earlier observations, particularly
given the high gene transfer eﬃcacies of the dihydroxy analogs
of the present lipids [32,33,35], our initial expectation was that
the presently designed lipids 1–5 would exhibit reasonably
good gene transfer properties in combination with either pure
DOPE or pure cholesterol. However, in stark contrast to this
expectation, the results in reporter gene expression assay (Figs.
2A–F) using p-CMV-SPORT-b-gal plasmid DNA revealed a
surprising transfection proﬁle. Except showing some weak to
moderate eﬃcacies in transfecting CHO cells at high lipid:D-
NA charge ratios in presence of DOPE, lipids 1–5 were found
to be either essentially transfection-incompetent or poorlyFig. 2. In vitro transfection eﬃciencies of lipids 1–5 in presence of pure comm
HepG2 (C, D) and CHO (E, F) cells in combination with usual co-lipids chol
commercially available reagent lipofectamine 2000. The b-galactosidase acti
units using standard curve constructed with pure (commercial) b-galactosida
the average value of two replicate experiments performed on the same day.transfecting in COS-1, HepG2 and CHO cells when used with
equimolar amounts of either pure DOPE or pure cholesterol as
co-lipid (Figs. 2A–F). Similarly poor transfection proﬁles of
lipids 1–5 were also observed when used in combination with
DOPC (data not shown).
3.1.2. Transfection properties of lipids 1–5 used in combination
with equimolar amounts ofDOPE, cholesterol andDOPC. After
observing the above-mentioned disappointing transfection
proﬁles of lipids 1–5used in combinationwith pure conventional
co-lipids, we decided to probe the inﬂuence of mixture of com-
monly used co-lipids such as DOPE, cholesterol and DOPC, if
any, in modulating the transfection proﬁle of lipids 1–5. To
our surprise, we observed remarkably improved transfection
eﬃcacies of lipids 1 and 2 when used in combination with equi-
molar amounts of DOPE, cholesterol and DOPC. Such im-
proved transfection proﬁles of lipids 1 and 2 were observed in
all three cells (COS-1, HepG2 and CHO) when lipids 1–5 wereon co-lipids. The eﬃciencies of the lipids in transfecting COS-1 (A, B),
esterol (A, C & E) and DOPE (B, D & F) were compared to that of the
vities in each well was converted to an absolute b-galactosidase milli-
se. All the lipids were tested on the same day and the data presented is
K. Mukherjee et al. / FEBS Letters 579 (2005) 1291–1300 1295used at 1:1:1:1 mole ratio of lipid:DOPE:Chol:DOPC (Fig. 3A–
C).Notably, the transfection eﬃcacies, of lipid 1, whenusedwith
1:1:1:1 mole ratio of lipid:DOPE:Chol:DOPC, were found to be
comparable to or better than that of commercially available
lipofectamine in all the three cells (Fig. 3A–C). The maximum
transfection eﬃcacies of lipid 1 in combination with the mixed
co-lipids were observed at lipid:DNA charge ratios of 1:1 or
3:1 in HepG2 and CHO cells (Fig. 3B and C) and at 9:1 lipid:D-
NA charge ratio in COS-1 cells (Fig. 3A). Towards evaluating
the transfection proﬁle at intermediate lipid:DNA charge ratios
of 2:1 and 3:2, the eﬃcacies of lipid 1 in transfecting the represen-
tative CHO cells were also separately measured at lipid:DNA
charge ratios of 9:1, 3:1, 2:1, 3:2 and 1:1. Lipid 1 in combination
with themixed co-lipids at intermediate lipid:DNAcharge ratios
of 2:1 and 3:2 were found to be about 2-fold less than those at
lipid:DNA charge ratio of 3:1 (Fig. 3D). However, lipid 1 used
with pure DOPE or pure cholesterol remained transfection-
incompetent at these intermediate lipid:DNA charge ratios in
CHO cells (Fig. 3D). In addition, towards gaining insights into
whether or not the enhanced transfection eﬃcacies of the present1
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Fig. 5. Whole cell histochemical X-gal staining assay. (A) Histochem-
ical whole cell X-gal staining of transfected CHO cells. Lipoplexes were
prepared with mixed co-lipids, conventional co-lipids DOPE and
cholesterol and lipid 1 (at lipid:DNA charge ratios of 3:1 and
lipid:DOPE:Chol:DOPC mole ratio of 1:1:1:1). Cells expressing b-
galactosidase were stained with X-gal as described in the text. (B)
Percents of representative X-gal stained CHO cells transfected with
lipid 1 used in combination with pure common co- lipids DOPE, Chol,
and mixed co-lipids (ML, DOPE:Chol:DOPC) and percents of
representative X-gal stained CHO cells transfected with lipids 2–5
and co-lipids (ML, DOPE:Chol:DOPC) at lipid:DNA charge ratio of
3:1. Cells expressing b-galactosidase were stained with X-gal as
described in the text. A minimum of 100 cells were counted to estimate
the percent of cells transfected. The values shown are average of three
independent measurements.
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into the origin of the observed enhanced transfection properties
of the present lipids in presence of equimolar mixtures of these
common co-lipids.
The phenomenal inﬂuence of mixture of common co-lipids
DOPE/Chol/DOPC towards imparting impressive transfection
properties to otherwise essentially transfection incompetent
cationic lipids 1–5 (Fig. 3A–C) was further conﬁrmed by whole
cell histochemical X-gal staining in representative CHO cells.
Fully consistent with the ﬁndings in the reporter gene expres-
sion assay (Fig. 3C), the number of X-gal stained CHO cells
transfected with lipid 1 used in combination with equimolar
amounts of DOPE, cholesterol and DOPC were observed to
be remarkably higher than that transfected with lipid 1 in com-
bination with pure co-lipids DOPE and cholesterol (Fig. 5A).
The percent of transfected and X-gal stained CHO cells for all
the lipids 1–5 in combination with equimolar amounts of the
mixed co-lipids as well as those for lipid 1 used with the co-lip-
ids DOPE and cholesterol alone at representative lipid:DNA
charge ratios of 3:1 are shown in Fig. 5B. The results summa-
rized in Figs. 3–5, taken together, demonstrate that lipid 1 with
the myristyl tail is the most eﬃcacious cationic lipid among lip-
ids 1–5 at lipid:DNA charge ratio of 3:1 and 1:1 when used in
combination with equimolar amounts of common co-lipids
DOPE:Chol:DOPC.
3.2. Lipid:DNA binding interactions and lipoplex sensitivities to
DNase I
Towards gaining insights into possible existence of any elec-
trostatic binding interactions diﬀerence between the plasmid
DNA and the present cationic lipids in combination with vary-
ing co-lipids, we performed both the conventional electropho-
retic gel retardation assay and DNase I sensitivity assays
across the lipid:DNA charge ratios 9:1, 3:1 and 1:1. Results
of the simple gel retardation assay (Fig. 6) for representative
lipid 1 revealed an interesting feature. Lipid 1 in combination
with mixed co-lipids was capable of completely inhibiting the
electrophoretic mobility of plasmid DNA across the entire li-pid:DNA charge ratios of 1:1–9:1 (Fig. 6). However, lipid 1
when used in combination with either DOPE or Cholesterol
co-lipids, was able to inhibit the mobility of DNA only at
the highest lipid:DNA charge ratios of 9:1 (Fig. 6). Such gel
patterns are consistent with the notion that sub-optimal li-
Fig. 6. Electrophoretic gel retardation assay. DNA binding gel patterns for lipoplexes prepared using cholesterol (lanes 3–5 from left), DOPE (lanes
6–8 from left) and fusogenic co-lipids (lanes 9–12 from left). The gel patterns for DNA associated with liposomes prepared using mixed co-lipids
(1:1:1 DOPE/Chol/DOPC) in absence of lipid 1 are shown in the extreme left lane. The lipid:DNA charge ratios are indicated at the top of each lane.
The details of treatment are as described in the text.
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ing the in vitro gene transfer eﬃcacies of the present lipids
when used in combination with a single conventional co-lipid.
An important point needs to be emphasized at this point of
discussion. The overall transfection eﬃcacy of a given cationic
lipid depends on the eﬃciencies of each of the multiple mech-
anistic steps involved in the lipofection pathway such as endo-
cytotic cellular uptake, release of plasmid DNA from the
endosomal compartments to cell cytoplasm, nuclear traﬃcking
of the endosomally released DNA and the ﬁnal transgene
expression [36–38]. Thus, a strongly DNA-binding lipid (such
as lipid 1 in combination with equimolar amounts of common
co-lipids, Fig. 6) can also be highly transfection-competent in
spite of the expected poor DNA dissociation from the lipoplex.
Next we measured the accessibilities of lipoplexes prepared
with varying co-lipids to DNase I by DNase I protection
experiments using the representative lipoplexes of lipid 1
across the lipid:DNA charge ratios 9:1, 3:1 and 1:1. After
the free DNA digestion by DNase I, the total DNA (both di-
gested and inaccessible DNA) was separated from the lipid and
DNase I (by extracting with organic solvent) and loaded onto
a 1% agarose gel. Electrophoretic gel patterns in such DNase I
sensitivity assay (Fig. 7A) revealed a rather surprising trend.
Both at 3:1 and 1:1 lipid:DNA charge ratios, band intensities
of inaccessible (and therefore undigested) DNA associated
with lipoplexes of conventional co-lipids (DOPE or choles-
terol) and lipid 1 were found to be signiﬁcantly reduced com-
pared to those associated with the transfection eﬃcient
lipoplexes made from lipid 1 and the mixed co-lipids across
the range of lipid:DNA charge ratios of 9:1 to 1:1 (Fig. 7A).
This result is consistent with the plasmid DNA associated with
lipoplexes of mixed co-lipids being more protected against at-
tack by DNase I than that complexed with lipoplexes of con-
ventional co-lipids (DOPE or cholesterol).
Towards probing any hitherto unsuspected inherent DNA-
protection properties of the co-lipid components (1:1:1 mole
ratio of DOPE:Cholesterol:DOPC), next we carried out the
DNase I protection experiment using plasmid DNA com-
plexed with only the three lipid components namely DOPE:-
Chol:DOPC (at a mole ratio of 1:1:1 without the presence of
lipid 1). Reasonably intense undigested DNA bands were de-tected in the gel in such control experiment (the extreme left
lane, Fig. 7A), a result in agreement with the existence of high
inherent DNA binding properties of equimolar mixtures of
common co-lipids. With a view to measure the DNase I sensi-
tivities of lipoplexes prepared with only cationic lipid and
DNA (in absence of any co-lipid), we performed the DNase
protection experiment using representative cationic lipid 1
across the entire lipid:DNA charge ratios of 9:1–0.1:1. The ob-
served electrophoretic gel pattern is shown in Fig. 7B. The re-
sults summarized in Figs. 7A and B demonstrate that at
lipid:DNA charge ratios 9:1 and 3:1, DNA associated with
the lipoplexes prepared in presence of mixed co-lipids and in
absence of any co-lipid are least DNase I sensitive. However,
at lipid:DNA charge ratio of 1:1, lipoplexes prepared with
mixed co-lipid appeared to be less DNase I sensitive than those
prepared with pure cationic lipid (Fig. 7A and B). Thus,
broadly speaking, the high gene transfer properties of the
present lipids may, in part, originate from such strong DNA
binding interactions of mixed co-lipids. However, the origin
of the strikingly reduced DNase I sensitivities for lipoplexes
1 prepared with mixed co-lipids is not clear at this stage of
investigation.
3.3. Particle sizes, zeta potentials and toxicity proﬁles
Measurements of particle sizes using dynamic laser light
scattering technique revealed that the sizes of all three repre-
sentative lipoplexes prepared using lipid 1 in combination with
DOPE, Cholesterol and DOPE/Chol/DOPC increase gradu-
ally from around 350 nm to about 700 nm in presence of
DMEM as the lipid:DNA charge ratios of lipoplexes increases
from 1:1 to 9:1 (Table 1). Thus, the lipoplex nano-sizes are not
likely to play any major role behind the observed contrasting
transfection proﬁles. In addition, the global surface potentials
of the lipoplexes prepared from lipid 1 in combination with
equimolar amounts of pure DOPE, pure cholesterol and
DOPE/Chol/DOPC were measured in presence of DMEM
using dynamic laser light scattering instrument equipped with
zeta-sizing capacity. Interestingly, across the entire lipid:DNA
charge ratios 9:1 to 1:1, the surface charges of the lipoplexes
prepared with both pure co-lipids and mixed co-lipids were
found to be overall negative in presence of DMEM varying
Fig. 7. DNase I protection experiment. (A) Lipoplexes were prepared with representative lipid 1 and cholesterol (lanes 3–5 from left), DOPE (lanes
6–8 from left) and co-lipids (lanes 9–12 from left). The gel patterns for DNA associated with liposomes prepared using mixed co-lipids (1:1:1 DOPE/
Chol/DOPC) in absence of lipid 1 are shown in the extreme left lane. (B) Lipoplexes were prepared with representative pure lipid 1 without the use of
any co-lipid. The lipid:DNA charge ratios are indicated at the top of each lane. The details of treatment are as described in the text.
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summarized in Tables 1 and 2 support the notion that both lip-
oplex size and surface potentials are unlikely to have any dom-
inant inﬂuence in modulating the transfection eﬃcacies of the
present lipids. Towards gaining some insights into the cell via-
bility proﬁles of the present transfection eﬃcient lipoplexes,MTT-based cell viability assays were performed in representa-
tive CHO cells across the entire range of lipid:DNA charge ra-
tios used in the actual transfection experiments. Percent cell
viabilities upon treatment with lipoplexes prepared from 1 to
5 were found to be high (70–100%) in CHO cells across the li-
pid:DNA charge ratios (Fig. 8).
Fig. 8. Percent cell viability upon treatment with lipoplexes. MTT-
assay based percent cell viabilities of lipoplexes prepared with lipids 1–
5 and mixed co-lipids (DOPE/Chol/DOPC) in representative CHO
cells. The percent cell viability values shown are average of triplicate
experiments performed on the same day.
Table 2
Zeta potential (mV) of lipoplexes in plain DMEM
No. Sample code Lipid:DNA charge ratio (n/p)
9:1 3:1 2:1 3:2 1:1
1. Lipid1:DOPE(1:1) 11.1 ± 0.9 16.1 ± 1.9 32.0 ± 1.4 28.4 ± 1.9 34.0 ± 1.1
2. Lipid1:CHOL(1:1) 13.9 ± 2.1 18.6 ± 3.3 33.8 ± 1.0 35.0 ± 1.1 36.1 ± 6.4
3. Lipid1:DOPE:CHOL:DOPC(1:1:1:1) 14.5 ± 2.7 20.7 ± 4.9 32.3 ± 2.9 31.5 ± 1.8 25.5 ± 7.6
Table 1
Sizes (nm) of lipoplexes in plain DMEM
No. Sample code Lipid:DNA charge ratio (n/p)
9:1 3:1 2:1 3:2 1:1
1. Lipid1:Chol(1:1) 710 ± 9.1 639.3 ± 9.4 512.0 ± 5.8 457.7 ± 1.8 494.3 ± 1.2
2. Lipid1:DOPE(1:1) 527.6 ± 5.6 522.9 ± 4.1 452.7 ± 6.9 450.3 ± 8.7 350.1 ± 3.68
3. Lipid1:DOPE:CHOL:DOPC(1:1:1:1) 698.5 ± 8.5 596.1 ± 5.9 552.6 ± 4.4 433.8 ± 5.7 352.2 ± 9.2
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Using a novel series of non-glycerol backbone based cationic
lipids with polar 2-hydroxyethyl and 2-aminoethyl head-group
functionalities (1–5, Fig. 1), we have demonstrated that com-
monly used co-lipids DOPE, cholesterol and DOPC, when
act in synergy, are capable of imparting high gene transfer
properties to cationic lipids which are otherwise either essen-
tially transfection incompetent or poorly transfecting when
used in combination with either DOPE or Cholesterol. Both
reporter gene expression assays in CHO, COS-1 and HepG2
cells and the whole cell histochemical X-gal staining assays
in representative CHO cells revealed that the improved gene
transfer properties of the present cationic lipids get severely
compromised when the cationic lipids are used in combina-
tions with pure individual co-lipid components. Electrophore-
sis gel patterns in DNase I sensitivity assay are consistent with
the notion that the high transfection properties of the present
cationic lipids in association with equimolar amounts ofDOPE, cholesterol and DOPC may partly originate due to
the signiﬁcantly reduced DNase I susceptibility of the corre-
sponding lipoplexes. Taken together, the present ﬁndings sup-
port the notion that use of common co-lipids in synergy may
turn out to be rewarding in future design of novel liposomal
transfection kits for use in non-viral gene therapy.
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